Equity

SHSSX

Health Sciences Opportunities Fund

Overview

Loading

Performance

Performance

Growth of Hypothetical $10,000

Performance chart data not available for display.
View full chart

Distributions

Interactive chart displaying fund performance. Javascript is required.

View full chart
  1y 3y 5y 10y
3.84 3.15 10.56 11.73
Benchmark (%) 2.87 4.63 10.79 10.92
Morningstar Category Avg. (%) 3.22 -2.35 8.65 8.95
Morningstar Ranking 94/176 48/158 48/135 5/113
Morningstar Quartile 2 2 2 1
Lipper Category Avg. (%) 4.65 -1.03 8.96 9.09
Lipper Ranking 64/125 26/111 25/94 5/76
Lipper Quartile 3 1 2 1
  YTD 1m 3m 1y 3y 5y 10y
3.84 4.39 5.86 3.84 9.75 65.17 203.28
Benchmark (%) 2.87 5.40 6.96 2.87 14.56 66.94 181.94
Morningstar Category Avg. (%) 3.22 9.55 9.77 3.22 -6.88 51.42 135.55
Lipper Category Avg. (%) 4.65 9.90 9.70 4.65 -1.90 54.64 142.57
  2019 2020 2021 2022 2023
Total Return (%) 25.64 19.78 12.09 -5.70 3.84
Benchmark (%) 22.11 19.34 18.60 -6.10 2.87
Morningstar Category Avg. (%) 26.23 27.63 6.88 -15.16 3.22

Performance is shown after deduction of ongoing charges. Any entry and exit charges are excluded from the calculation.

The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted. Effective as of May 31, 2018, the performance information for periods prior to the inception date of the share class shows the performance of the Fund’s Investor A Shares. The performance of this share class would be substantially similar to Investor A Shares because this share class and Investor A Shares invest in the same portfolio of securities and performance would only differ to the extent that this share class and Investor A Shares have different expenses. For performance periods prior to May 31, 2018, the performance information for periods prior to the inception date of the share class shows the performance of the Fund’s Investor A Shares, adjusted to reflect the fees and expenses applicable to such share class. See the fund prospectus for more details.

Key Facts

Key Facts

Size of Class (Millions) as of Mar 18, 2024 $4,434.5 M
Size of Fund (Millions) as of Mar 18, 2024 $8,463.6 M
Share Class launch date Oct 16, 2000
Asset Class Equity
Morningstar Category Health
Lipper Classification Health/Biotech Funds
Benchmark Index Russell 3000 HealthCare Index (USD)
CUSIP 091937540
Distribution Frequency Annual
Number of Holdings as of Feb 29, 2024 133
Max Offer Price as of Mar 18, 2024 $74.55
Open to New Investors Yes
Turnover Percent in the Annual Report as of May 31, 2023 29%

Portfolio Characteristics

Portfolio Characteristics

P/B Ratio as of Feb 29, 2024 5.31
P/E Ratio - Forward as of Feb 29, 2024 20.76
Average Market Cap (Millions) as of Feb 29, 2024 $ 113,551,411.6 M
Alpha (3y) as of Feb 29, 2024 -0.02
R-Squared (3y) as of Feb 29, 2024 97.46
Beta (3y) as of Feb 29, 2024 0.94
Best 3-Month Return Over the Last 3 Years 3 months ending Jan 31, 2024 13.26%
Worst 3-Month Return Over the Last 3 Years 3 months ending Feb 28, 2023 -7.03%
Fund Standard Deviation (3y) as of Feb 29, 2024 14.05
Active Share as of Feb 29, 2024 27.66%

This information must be preceded or accompanied by a current prospectus. For standardized performance, please see the Performance section above.

Sustainability Characteristics

Sustainability Characteristics

Sustainability Characteristics provide investors with specific non-traditional metrics. Alongside other metrics and information, these enable investors to evaluate funds on certain environmental, social and governance characteristics. Sustainability Characteristics do not provide an indication of current or future performance nor do they represent the potential risk and reward profile of a fund. They are provided for transparency and for information purposes only. Sustainability Characteristics should not be considered solely or in isolation, but instead are one type of information that investors may wish to consider when assessing a fund. Learn more


This fund does not seek to follow a sustainable, impact or ESG investment strategy. The metrics do not change the fund’s investment objective or constrain the fund’s investable universe, and there is no indication that a sustainable, impact or ESG investment strategy will be adopted by the fund. For more information regarding the fund's investment strategy, please see the fund's prospectus.


Review the MSCI methodologies behind Sustainability Characteristics using the links below.

MSCI ESG Fund Rating (AAA-CCC) as of Feb 21, 2024 A
MSCI ESG % Coverage as of Feb 21, 2024 97.60%
MSCI ESG Quality Score (0-10) as of Feb 21, 2024 6.9
MSCI ESG Quality Score - Peer Percentile as of Feb 21, 2024 69.46%
Fund Lipper Global Classification as of Feb 21, 2024 Equity Sector Healthcare
Funds in Peer Group as of Feb 21, 2024 514
MSCI Weighted Average Carbon Intensity (Tons CO2E/$M SALES) as of Feb 21, 2024 15.22
MSCI Weighted Average Carbon Intensity % Coverage as of Feb 21, 2024 96.11%
All data is from MSCI ESG Fund Ratings as of Feb 21, 2024, based on holdings as of Aug 31, 2023. As such, the fund’s sustainable characteristics may differ from MSCI ESG Fund Ratings from time to time.

To be included in MSCI ESG Fund Ratings, 65% (or 50% for bond funds and money market funds) of the fund’s gross weight must come from securities with ESG coverage by MSCI ESG Research (certain cash positions and other asset types deemed not relevant for ESG analysis by MSCI are removed prior to calculating a fund’s gross weight; the absolute values of short positions are included but treated as uncovered), the fund’s holdings date must be less than one year old, and the fund must have at least ten securities.

Business Involvement

Business Involvement

Business Involvement metrics can help investors gain a more comprehensive view of specific activities in which a fund may be exposed through its investments.


Business Involvement metrics are not indicative of a fund’s investment objective, and, unless otherwise stated in fund documentation and included within a fund’s investment objective, do not change a fund’s investment objective or constrain the fund’s investable universe. For more information regarding a fund's investment strategy, please see the fund's prospectus.


Review the MSCI methodology behind the Business Involvement metrics, using links below.

MSCI - Controversial Weapons as of - -
MSCI - UN Global Compact Violators as of - -
MSCI - Nuclear Weapons as of - -
MSCI - Thermal Coal as of - -
MSCI - Civilian Firearms as of - -
MSCI - Oil Sands as of - -
MSCI - Tobacco as of - -

Business Involvement Coverage as of - -
Percentage of Fund not covered as of - -
BlackRock business involvement exposures as shown above for Thermal Coal and Oil Sands are calculated and reported for companies that generate more than 5% of revenue from thermal coal or oil sands as defined by MSCI ESG Research. For the exposure to companies that generate any revenue from thermal coal or oil sands (at a 0% revenue threshold), as defined by MSCI ESG Research, it is as follows: Thermal Coal -% and for Oil Sands -%.

Business Involvement metrics are calculated by BlackRock using data from MSCI ESG Research which provides a profile of each company’s specific business involvement. BlackRock leverages this data to provide a summed up view across holdings and translates it to a fund's market value exposure to the listed Business Involvement areas above.


Business Involvement metrics are designed only to identify companies where MSCI has conducted research and identified as having involvement in the covered activity. As a result, it is possible there is additional involvement in these covered activities where MSCI does not have coverage. This information should not be used to produce comprehensive lists of companies without involvement. Business Involvement metrics are only displayed if at least 1% of the fund’s gross weight includes securities covered by MSCI ESG Research.

ESG Integration

ESG Integration

ESG integration is the practice of incorporating financially material environmental, social and governance (ESG) data or information into the investment decision process with the objective of enhancing risk-adjusted returns of our clients’ portfolios. Unless otherwise stated in Fund documentation or included within the Fund's investment objective, inclusion of this statement does not imply that the Fund has an ESG-aligned investment objective or strategy, but rather describes how ESG data or information is considered as part of the overall investment process.

The Fund manager includes ESG considerations in combination with other information in the research and decision phases of the investment process. The Fund manager conducts regular portfolio reviews between with the Risk and Quantitative Analysis group and with the Chief Investment Officers. Where appropriate, these reviews include discussion of the portfolio's exposure to material ESG risks, as well as exposure to sustainability-related business involvements, climate-related metrics, and other factors.

Fees

Fees

as of current prospectus
Gross Expense Ratio 0.84%
Net Expense Ratio 0.84%

Net Expense Ratio excluding Investment Related Expenses is 0.84%

  • Acquired Fund Fees and Expenses 0.00%
  • Interest expense 0.00%

Ratings

Ratings

Morningstar Rating

5 stars
Overall Morningstar Rating for Health Sciences Opportunities Fund, Class Inst, as of Feb 29, 2024 rated against 158 Health Funds based on risk adjusted total return.

Lipper Leader

 
 
 
 
Overall Lipper Leaders ratings based on an equal-weighted average of percentile ranks for each measure over 3-, 5-, and 10-year periods (if applicable) and do not take into account the effects of sales charges for these categories (Consistent Return, Preservation, Total Return, Expense, and Tax Efficiency) as of Feb 29, 2024 out of 111, 12,519, 111, 63 and 108 Funds, respectively in Lipper's Health/Biotech Funds classification.

Morningstar Medalist Rating

Morningstar Medalist Rating - BRONZE
Morningstar has awarded the Fund a Bronze medal. (Effective Jan 31, 2024)

Holdings

Holdings

as of Feb 29, 2024
Name Weight (%)
ELI LILLY AND COMPANY 9.99
UNITEDHEALTH GROUP INC 8.31
ABBVIE INC 5.32
BOSTON SCIENTIFIC CORPORATION 4.89
MERCK & CO INC 4.80
Name Weight (%)
ABBOTT LABORATORIES 3.65
AMGEN INC 3.39
DANAHER CORPORATION 3.24
STRYKER CORPORATION 2.78
INTUITIVE SURGICAL INC 2.76
Name Weight (%) Shares Market Value
Holdings are subject to change. Fund holdings and allocations shown are unaudited, and may not be representative of current or future investments. The Fund is actively managed and its details, holdings and characteristics will vary. Holdings shown should not be deemed as a recommendation to buy or sell securities. The user relies on this data at its own risk and neither BlackRock nor any other party makes any representations or express or implied warranties (which are expressly disclaimed) nor shall they incur any liability for any errors or omissions in the data.

Exposure Breakdowns

Exposure Breakdowns

as of Feb 29, 2024

% of Market Value

Type Fund Benchmark Net
as of Feb 29, 2024

% of Market Value

Type Fund Benchmark Net
as of Feb 29, 2024

% of Market Value

Type Fund Benchmark Net
as of Feb 29, 2024

% of Market Value

Type Fund Benchmark Net
Negative weightings may result from specific circumstances (including timing differences between trade and settle dates of securities purchased by the funds) and/or the use of certain financial instruments, including derivatives, which may be used to gain or reduce market exposure and/or risk management.

Allocations are subject to change.

Portfolio Managers

Portfolio Managers

Erin Xie
Head of the Health Sciences team
Xiang Liu
BlackRock Health Sciences Team
Portfolio Manager

Literature

Literature

 

There are many ways to access BlackRock Funds, learn how you can add them to your portfolio